SPECIAL OFFER FROM SIRIUS-BIOTECH
Valid until: December 31th, 2015
Antibodies to B-Fibronectin, a marker of angiogenesis.
B-FN is accumulated around neovasculature during angiogenic processes and thereby provides one of the best marker for angiogenesis and it is a component of the ECM of the niche of stem cells.
Monoclonal antibodies BC-1 and C6: 1mg 600 Euro
Send your orders at : info@sirius-biotech.com
Human glioblastoma vascular structures stained with antibodies to B-FN (a). A zoom view is shown in (c). In (b), normal brain stained with antibodies to B-FN.
The monoclonals BC-1 and C6 recognize the fibronectin isoform containing the extra domain B (ED-B). The figure above shows the staining of vascular structure of a human glioblastoma while normal human brain sections are completely negative. In cultured transformed cells and in malignancies, the splicing pattern of FN pre-mRNA is altered, leading to an increased expression of FN isoforms containing the domains regulated by alternative splicing. In particular, the ED-B containing fibronectin isoform (B-FN), which, with some very rare exceptions, is undetectable in normal adult tissues, exhibits a much greater expression in fetal and tumor tissues, as well as during wound healing.
B-Fibronectin References:
- Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.
Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE.
EMBO J. 1987;6:2337-42. - A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.
Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG.
J Cell Biol.1989 ;108:1139-48. - The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.
Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L.
Int J Cancer. 1994;59:612-8. - Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.
Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L.
Int J Cancer. 1994 ;59:11-6. - Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.
Kosmehl H, Berndt A, Katenkamp D.
Virchows Arch. 1996 ; 429:311-22. - Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.
Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L.
Am J Pathol. 2002 ;161:1695-700. - Tumour vascular targeting.
Neri D, Bicknell R.
Nat Rev Cancer. 2005; 5:436-46. - Fibronectin as target for tumor therapy.
Kaspar M, Zardi L, Neri D.
Int J Cancer. 2006 15;118:1331-9. - Positron emission tomography tracers for imaging angiogenesis.
Haubner R, Beer AJ, Wang H, Chen X.
Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S86-103. - A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis- associated extra type III domain B.
Balza E, Sassi F, Ventura E, Parodi A, Fossati S, Blalock W, Carnemolla B, Castellani P, Zardi L, Borsi L.
Int J Cancer. 2009; 125:751-758. - Differentiation between high and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.
Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L.
Am J Pathol. 2002; 161(5):1695-700.